GSK to Acquire 36.5% Stake in Consumer Healthcare Joint Venture, Established with Novartis

 GSK to Acquire 36.5% Stake in Consumer Healthcare Joint Venture, Established with Novartis

GSK to Acquire 36.5% Stake in Consumer Healthcare Joint Venture, Established with Novartis

Shots:

  • Novartis to receive $13B (£9.2B) as total deal value from GSK. GSK to acquire 36.5% stake (63.5% already acquired in 2014) in Consumer Healthcare Joint Venture, formed in 2014 with Novartis
  • The focus of the agreement is to utilize the venture for manufacturing of OTC, oral health brands, pharmaceutical and vaccines such as Sensodyne and Eno in Vemgal, Karnataka and Nashik
  • Additionally, GSK plans to review Horlicks and healthcare nutrition products to support the transaction. In April 2014, GSK and Novartis signed a joint agreement to create Consumer Healthcare business focusing on Consumer Healthcare, Vaccines and Oncology products

Click here to read full press release/ article | Ref: GSK | Image:  Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post